AbbVie presents new data across its blood cancer portfolio at EHA 2026

AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Featured data from AbbVie’s blood cancer portfolio and pipeline include 21 oral and poster presentations, highlighting the investigational compound etentamig (ABBV-383), and approved therapies, EPKINLY^® (epcoritamab-bysp) (TEPKINLY^® in the EU), VENCLEXTA^® (venetoclax) (VENCLYXTO^® in the EU) and DECNUPAZ™ (pivekimab sunirine-pvzy).

“The compelling data we are presenting at EHA reflect AbbVie’s robust portfolio and pipeline and our ongoing work to advance the treatment and understanding of hematologic cancers,” said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. “With this research, we continue our commitment to pioneering innovative solutions that have the potential to elevate standards of care for patients and help address the most pressing challenges in treating blood cancers.”

Key oral presentations of epcoritamab data include:

• Treatment impact of epcoritamab with lenalidomide and rituximab in relapsed or refractory (R/R) FL
  • A subgroup analysis of the Phase 3 EPCORE FL-1 trial (NCT05409066) of fixed-duration epcoritamab, in combination with rituximab plus lenalidomide (E+R²) for patients with R/R FL (n=243), was performed to determine if the efficacy benefit and tolerability of E+R² extended across clinically relevant subgroups, including patients with higher- and lower-risk disease features, compared to R².¹
  • Between Follicular Lymphoma International Prognostic Index (FLIPI) subgroups, overall response rate (ORR) was numerically higher with E+R² compared to R² (FLIPI 0–2, 96.5% vs 84.8%; FLIPI 3–5, 93.0% vs 72.6%).¹ A similar trend was seen in those with progression of disease less than or equal to two years from the date of initial frontline therapy (POD24).¹
  • Across the age subgroups, ORR and complete response rates (CRR) for E+R² and R² for ≥65 were (94.3% vs 80.2% and 80.7% vs 44.3%, respectively) and <65 (95.5% vs 78.4% and 83.9% vs 54.0%, respectively). Progression-free survival (PFS) hazard ratios (HRs) (95% CIs) for E+R² and R² for the NHL-5 low co-morbidity index score were (0.27 [0.17–0.42]) and NHL-5 high + intermediate were (0.14 [0.06–0.29]).¹
  • The E+R² safety profile across all subgroups was consistent with the overall trial population, with no new safety signals.¹

• Efficacy data of epcoritamab following systemic therapy in R/R large B-cell lymphoma (LBCL)
  • EPCORE DLBCL-1 (EudraCT No. 2020-003016-27) is a randomized Phase 3 trial in R/R LBCL evaluating epcoritamab, a CD3×CD20 bispecific antibody, monotherapy. The study showed a statistically significant improvement in PFS versus investigator’s choice of chemoimmunotherapy (CIT) — either rituximab plus gemcitabine plus oxaliplatin or bendamustine plus rituximab (HR 0.74 [95% CI, 0.60–0.92]; P=0.0059; 24-month PFS: 30% vs 13%). The study did not demonstrate a statistically significant improvement in overall survival (OS) (HR: 0.96 [95% CI, 0.77–1.20]). There was no OS detriment per pre-specified criteria.*²
  • Epcoritamab reported a CRR of 38% and CIT 26%; (nominal P value 0.0032), duration of response (DOR) (median DOR 37 vs 6 months; duration of complete response (DOCR) NR vs 11 months, respectively) and time to next treatment (TTNT) (7 vs 4 months, respectively; nominal P value <0.0001).²
  • Higher rates of grade 3–4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%) were reported in the epcoritamab arm. Grade 5 treatment-emergent adverse events (TEAEs) occurred in 17% vs 6% (exposure-adjusted, 1.5 vs 1.8 per 100 pt-mo) and were largely attributable to grade 5 COVID-19 (9% vs 2%).²

*OUS the protocol and SAP were amended to include dual primary endpoints of OS and PFS

The following studies featuring venetoclax, etentamig and pivekimab sunirine-pvzy data will also be shared as oral and poster presentations:

• Predicted efficacy of venetoclax-based therapies in CLL based on genetic biomarkers
  • Results from the Phase 3 GAIA/CLL13 (NCT02950051) trial evaluating fixed-duration venetoclax-based combinations (with rituximab, obinutuzumab and obinutuzumab plus ibrutinib) as a chemotherapy-free alternative to chemoimmunotherapy (fludarabine, cyclophosphamide and rituximab or bendamustine and rituximab) in fit, previously untreated CLL patients lacking del(17p) or TP53 mutations.³
  • Venetoclax in combination with rituximab and obinutuzumab plus ibrutinib in previously untreated CLL patients lacking del(17p) or TP53 mutations are investigational combinations not approved in the EU.

• Efficacy and safety data of venetoclax-obinutuzumab combination in previously untreated CLL
  • Results from the open-label Phase 3 CLL14 trial (NCT02242942) comparing the efficacy and safety of venetoclax in combination with obinutuzumab to obinutuzumab plus chlorambucil in previously untreated patients with CLL and coexisting medical conditions.⁴

• Real-world management practices with venetoclax-based therapy for AML
  • Results from the prospective observational study, REVIVE (NCT03987958), examining the effect of antimicrobial prophylaxis, post-remission administration of G-CSF and treatment initiation setting on safety and effectiveness outcomes with venetoclax plus hypomethylating agents (HMA) in newly diagnosed AML patients unfit for intensive chemotherapy.⁵

• Etentamig in patients with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)-targeted therapy
  • Results from Arm B of the MONVISO study (NCT05650632), evaluating a flat dose of etentamig in patients with RRMM with at least two prior lines of therapy, including triple-class and prior BCMA exposure. The Phase 1b study is assessing dose optimization and safety.⁶
  • Etentamig is an investigational therapy not approved in the EU.

• Longer term safety and efficacy data of etentamig monotherapy in R/R light chain amyloidosis
  • Updated results from M24-209 (NCT06158854), evaluating etentamig monotherapy in BCMA-targeted therapy-naïve patients with relapsed/refractory immunoglobulin light chain amyloidosis. The open-label Phase 1/2 study is assessing dose escalation safety and efficacy.⁷
  • Etentamig is an investigational therapy not approved in the EU.

• Efficacy data of pivekimab sunirine-pvzy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) with baseline skin involvement in the CADENZA study
  • Post-hoc analysis from CADENZA (NCT03386513), evaluating the first-line use of pivekimab sunirine-pvzy in patients with BPDCN and varying degrees of skin involvement. The open-label Phase 1/2 study is assessing overall response rate, overall survival and percentage of eligible patients approved to proceed with a stem cell transplant.⁸
  • Pivekimab sunirine-pvzy is an investigational therapy not approved in the EU.

View details on key oral and poster presentations at the EHA 2026 Congress HERE.